LifeVantage Corp. 10-Q Summary: Quarter Ended December 31, 2025
Business Context and Reporting Period
This summary covers LifeVantage Corporation's (LFVN) Form 10-Q for the quarterly period ended December 31, 2025, and the six months ended on that date. LifeVantage is a direct-selling company focused on nutrigenomics, offering dietary supplements (including the flagship Protandim line), skin care, and nootropics. The company operates in a single segment across the Americas and Asia/Pacific & Europe regions.
Key Financial Metrics
| Metric | 3 Months Ended Dec 31, 2025 | 6 Months Ended Dec 31, 2025 | 3 Months Ended Dec 31, 2024 | 6 Months Ended Dec 31, 2024 |
|---|---|---|---|---|
| Net Revenue | $48.9 million | $96.5 million | $67.8 million | $115.0 million |
| Gross Profit | $36.2 million (74.0%) | $74.0 million (76.7%) | $54.6 million (80.5%) | $92.3 million (80.3%) |
| Operating Income | $0.5 million | $2.8 million | $3.4 million | $6.0 million |
| Net Income | $0.3 million | $2.4 million | $2.6 million | $4.4 million |
| Diluted EPS | $0.02 | $0.19 | $0.19 | $0.34 |
| Cash & Equivalents | $10.2 million | Balance Sheet (Dec 31, 2025) | ||
| Working Capital | $19.5 million | Balance Sheet (Dec 31, 2025) | ||
| Debt Outstanding | $0 | Revolving Credit Facility |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 27.8% year-over-year for the quarter and 16.1% for the six-month period. The primary driver was a significant decline in sales of the MindBody GLP-1 System, which dropped $16.2 million in the quarter and $10.6 million in the six-month period compared to the prior year.
- Margin Compression: Gross profit margins declined from 80.5% to 74.0% (quarterly) and 80.3% to 76.7% (six-month). This was primarily due to a $2.4 million inventory obsolescence charge related to the MindBody GLP-1 System, alongside increased shipping and warehouse expenses.
- Active Accounts: Total active accounts (consultants and customers) fell 21.2% year-over-year to 115,000. Active customers in the Americas dropped 32.5% to 54,000.
- Acquisition: In October 2025, the company acquired critical assets of LoveBiome for approximately $4.2 million (including earnouts). This contributed $4.1 million in revenue for the quarter but did not fully offset the decline in other product lines.
- Cash Flow: Operating cash flow decreased significantly to $0.5 million for the six months ended Dec 31, 2025, compared to $8.6 million in the prior year, largely due to the payment of previously accrued employee incentive compensation and trip expenses.
Guidance, Outlook, and Risks
- Outlook: Management plans to continue refining product offerings internationally, specifically expanding the MindBody GLP-1 System and LoveBiome product lines in fiscal year 2026. The company believes current cash balances and operating cash flows are sufficient for the next 12 months.
- Capital Allocation: The company paid cash dividends of $0.045 per share in both Q3 and Q4 of fiscal 2026. It also repurchased 44,000 shares for $0.6 million during the six-month period, with $16.7 million remaining under its repurchase program.
- Key Risks:
- Dependence on a few products (Protandim, TrueScience, LifeVantage lines represented ~78% of quarterly revenue).
- Ability to retain independent consultants and attract new customers.
- Inventory obsolescence risks, particularly for new product launches.
- Compliance with financial covenants on the $5.0 million revolving credit facility (currently compliant with no balance outstanding).
Investor Verification Checklist
- Inventory Valuation: Verify the $2.4 million inventory obsolescence charge related to the MindBody GLP-1 System and assess future write-down risks.
- Active Account Trends: Monitor the 21.2% decline in active accounts and the 32.5% drop in active customers in the Americas to gauge future revenue sustainability.
- LoveBiome Integration: Track the performance of the LoveBiome acquisition against revenue targets required for earnout payments ($0.2 million current, $0.3 million long-term).
- Liquidity Position: Confirm the sustainability of the dividend policy ($0.045/share) given the sharp reduction in operating cash flow.
- Product Mix: Assess the trajectory of the MindBody GLP-1 System sales, which drove the majority of the revenue decline.